Leveraging the qMSP‐based technique, Exact Science developed a multitarget HCC blood test including two methylated DNA markers (MDMs; HOXA1, and TSPYL5), AFP, and sex.[10, 12, 13] This assay yielded a sensitivity of 82.1% in Barcelona Clinic Liver Cancer (BCLC) stage 0–A cases at a specificity of 86.9% in LC/HVI controls in the clinical validation,[13] and there remains significant potential for further improvement in performance. The gene discussed is AFP; the disease is hepatocellular carcinoma.